STOCK TITAN

Biocryst Pharmaceuticals Inc - BCRX STOCK NEWS

Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.

BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.

Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.

Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced its participation in several upcoming investor conferences. The company will present at:

  • The 22nd Annual Needham Virtual Healthcare Conference on April 19 at 8:45 a.m. ET
  • The BofA Securities 2023 Health Care Conference in Las Vegas on May 10 at 6:00 p.m. ET
  • The JMP Securities Life Sciences Conference in New York on May 16 at 2:30 p.m. ET
  • The RBC Capital Markets Global Healthcare Conference in New York on May 17 at 8:00 a.m. ET

Live audio webcasts and replays will be accessible in the Investors & Media section of BioCryst’s website. Known for developing oral medicines for rare diseases, BioCryst's ORLADEYO (berotralstat) is already approved in the U.S. and other markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
-
Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the grant of stock options and restricted stock units (RSUs) to six new employees, totaling 124,300 shares in stock options and 40,350 shares in RSUs, effective March 31, 2023. The stock options, priced at $8.34 per share, align with BioCryst’s closing stock price on the grant date. Vesting occurs in four equal annual installments, contingent on continued employment, with a 10-year term for the options. This action complies with Nasdaq Listing Rule 5635(c)(4) and supports the company's strategy to attract talent in its mission to develop innovative treatments for rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Dr. Nancy Hutson as chair of its board of directors, effective immediately, succeeding Bob Ingram. Dr. Hutson has over 30 years of experience in the pharmaceutical industry, having previously led global R&D at Pfizer. She has been with BioCryst since 2012 and has contributed significantly to various board committees. Under her leadership, the company aims to continue developing innovative therapies for rare diseases, including its approved oral medicine, ORLADEYO (berotralstat), and its ongoing clinical development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced the granting of stock options and restricted stock units (RSUs) to 12 newly-hired employees. The total grants include options for 110,400 shares and RSUs for 51,300 shares, effective February 28, 2023. The options have an exercise price of $8.85, aligning with the company's common stock closing price on the grant date. Vesting occurs in four equal annual installments, contingent upon the employees' continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of BioCryst's Inducement Equity Incentive Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals announced significant findings from the APeX-S and APeX-2 clinical trials for ORLADEYO (berotralstat), an oral medication for hereditary angioedema (HAE). The final results showed a median attack rate of 0.0 attacks per month in 20 of 24 months. This treatment is well-tolerated, with no new safety signals, and demonstrates sustained reductions in attacks and improved quality of life among patients. These findings were presented at the 2023 AAAAI annual meeting. Real-world data further supports the effectiveness of ORLADEYO, highlighting the ongoing need for accessible treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in two upcoming healthcare conferences. The company will present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 8, 2023, at 12:50 p.m. ET, and at the Barclays 2023 Global Healthcare Conference in Miami, FL, on March 14, 2023, at 9:30 a.m. ET. Investors can access live webcasts and replays via the Investors & Media section of BioCryst's website. The company focuses on developing innovative oral medicines for rare diseases with high unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.08%
Tags
conferences
-
Rhea-AI Summary

BioCryst Pharmaceuticals reported Q4 2022 net revenue of $70.7 million, with a full-year total of $251.6 million, reflecting a 72% year-over-year increase. The company projects 2023 revenue for ORLADEYO to reach no less than $320 million, anticipating peak sales of $1 billion. Financial results revealed a net loss of $71.5 million in Q4, up from $17.8 million a year prior. Total cash and investments as of December 31, 2022, stood at $443.9 million. R&D and SG&A expenses increased, attributed to higher investments for ORLADEYO's launch and ongoing programs. The company is focused on expanding its market reach with robust demand for ORLADEYO, now available in 15 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.29%
Tags
-
Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announces it will report Q4 2022 financial results on February 21, 2023. The management will host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update. Investors can access the live call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live webcast and replay will be available on the company’s website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases with significant unmet medical needs, including products like ORLADEYO® and RAPIVAB®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences earnings
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to 20 newly-hired employees as part of their incentive compensation plan. A total of 287,200 stock options and 101,700 RSUs will vest annually over four years, with a set exercise price of $10.55 per share, equating to the stock's closing price on the grant date of January 31, 2023. These grants comply with Nasdaq regulations. BioCryst focuses on developing novel medications for rare diseases, including ORLADEYO and RAPIVAB, both approved in various markets. For further details, visit their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
Biocryst Pharmaceuticals Inc

Nasdaq:BCRX

BCRX Rankings

BCRX Stock Data

1.55B
202.17M
1.44%
81.14%
7.66%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States
DURHAM